Is a complete DRUG research report available?

No complete published report is available for Bright Minds Biosciences Inc. (DRUG) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Bright Minds Biosciences Inc. (DRUG)

NASDAQ: DRUG · USD

$74.6

+3.57 (+5.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first DRUG analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	731.4M
Net income (ttm)	-19.6M
EPS (ttm)	-$2.48
Shares out	9.8M
Volume	207,012
Beta	0.10
Price target	$167	+123.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -19.6M
EPS (ttm): -$2.48
Market cap: 731.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All DRUG indicators

Market & fundamental data

Available fields

169

Groups with data

Currency

CAD

Showing 169 of 169 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001827401
Company name	Bright Minds Biosciences Inc.
Country	United States
Country code	US
Cusip	10919W405
Employees	26
Employees Change	25%
Employees Change Percent	2,500
Enterprise value	$510.5M
Exchange	NASDAQ
Financial currency	CAD
First seen	2026-05-09
Industry	Biotechnology
Isin	CA10919W4056
Last refreshed	2026-07-31
Market cap	$731.4M
Market cap category	Small-Cap
Price	$74.63
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	DRUG
Website	https://brightmindsbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.68%
P/B ratio	3.31x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-19.6M
Net Income Growth Years	0%
Profit Per Employee	$-753,699
ROA	-10.44
Roa5y	-40.07
ROCE	-9.98
ROE	-15.02
Roe5y	-69.2
ROIC	-10.56

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	114.44%
Cagr3y	166.28%
Cagr5y	25.95%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$223.8M
Cash	$221.9M
Current Assets	$222.9M
Current Liabilities	$2.7M
Debt	$58,838
Debt Equity	$0
Equity	$221M
Interest Coverage	-642.7
Liabilities	$2.7M
Long Term Assets	$902,097
Long Term Liabilities	$10,435
Net Cash	$221.8M
Net Cash By Market Cap	$30.33
Net Cash Growth	457.72%
Net Debt Equity	$-1
Tangible Book Value	$221M
Tangible Book Value Per Share	$22.53
WACC	4.78

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	81.48
Net Working Capital	$-823,641
Quick ratio	81.1
Working Capital	$221M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-42.99%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	114.33%
200-day SMA	75.67
3Y total return	1,789.37%
50-day SMA	71.96
50-day SMA vs 200-day SMA	50under200
5Y total return	216.9%
All Time High	123.8
All Time High Change	-39.69%
All Time High Date	2026-01-06
All Time Low	0.93
All Time Low Change	7,924.73%
All Time Low Date	2024-04-30
ATR	4.55
Beta	0.1
Ch YTD	-4.37
High	75.5
High52	123.8
High52 Date	2026-01-06
High52ch	-39.69%
Low	71.45
Low52	31.8
Low52 Date	2025-07-31
Low52ch	134.69%
Ma50ch	3.72%
Price vs 200-day SMA	-1.37%
RSI	54.32
RSI Monthly	62.7
RSI Weekly	49.93
Sharpe ratio	1.37x
Sortino ratio	2.42
Total Return	-42.99%
Tr YTD	-4.37
Tr1m	7.88%
Tr1w	4.69%
Tr3m	-16.25%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	5
Analyst Price Target Top	$164
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.39
Operating Income	$-22.1M
Price target	$167
Price Target Change	$123
Price Target Change Top	$120

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5,126,760%
Float Percent	52.25%
Net Borrowing	-74,239.3
Shares Insiders	16.82%
Shares Institutions	62.03%
Shares Out	9,812,061
Shares Qo Q	23.56%
Shares Yo Y	42.99%
Short Float	18.64%
Short Ratio	2.98
Short Shares	9.74

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted OCF	-17,638,292.6
Average Volume	248,336.65x
Bv Per Share	22.53
Ch1m	7.88
Ch1w	4.69
Ch1y	114.3
Ch3m	-16.25
Ch3y	1,789.4
Ch5y	216.9
Ch6m	-9.52
Change	5.02%
Change From Open	4.25
Close	71.06
Days Gap	0.75
Depreciation Amortization	51,702
Dollar Volume	15,449,305.6
Earnings Date	2026-08-13
Earnings Time	bmo
EBIT	$-22.1M
EPS	$-2.48
F Score	1
Financing CF	197,124,910
Fiscal Year End	September
Founded	2,019
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-05-19
Last Report Date	2026-03-31
Last Split Date	2023-07-14
Last Split Type	Reverse
Last10k Filing Date	2024-12-31
Ma150	78.59
Ma150ch	-5.04%
Ma20	73.03
Ma20ch	2.19%
Net CF	181,975,232
Next Earnings Date	2026-08-10
Open	71.59
Optionable	No
Position In Range	78.52
Ppne	51,654.8
Price Date	2026-07-30
Ptbv Ratio	3.31
Relative Volume	0.83x
Share Based Comp	3,496,459
Tr6m	-9.52%
Us State	New York
Volume	207,012

Bright Minds Biosciences Inc. (DRUG)

Coverage state: Market snapshot only — no published research

Generate the first DRUG analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · DRUG

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DRUG indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on DRUG

Frequently asked questions